Cowen and Company cut shares of Nivalis Therapeutics Inc. (NASDAQ:NVLS) from an outperform rating to a market perform rating in a research note released on Tuesday morning.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Nivalis Therapeutics from a sell rating to a buy rating and set a $8.50 price objective on the stock in a research report on Thursday, October 20th. Piper Jaffray Cos. reissued a buy rating and set a $16.00 target price on shares of Nivalis Therapeutics in a research report on Tuesday, August 30th. HC Wainwright reissued a buy rating on shares of Nivalis Therapeutics in a research report on Monday, August 8th. Stifel Nicolaus downgraded shares of Nivalis Therapeutics from a buy rating to a hold rating and dropped their target price for the stock from $16.00 to $3.25 in a research report on Tuesday. Finally, Robert W. Baird downgraded shares of Nivalis Therapeutics from an outperform rating to a neutral rating and dropped their target price for the stock from $29.00 to $3.00 in a research report on Tuesday. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Nivalis Therapeutics presently has a consensus rating of Hold and a consensus target price of $9.00.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:NVLS)

Nivalis Therapeutics (NASDAQ:NVLS) opened at 2.57 on Tuesday. The firm has a 50-day moving average of $6.46 and a 200 day moving average of $5.84. Nivalis Therapeutics has a 52-week low of $3.68 and a 52-week high of $9.45. The company’s market capitalization is $39.95 million.

Nivalis Therapeutics (NASDAQ:NVLS) last issued its quarterly earnings data on Monday, November 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.11. Equities analysts predict that Nivalis Therapeutics will post ($2.10) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was published by Daily Political and is the propert of of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The correct version of this report can be viewed at http://www.dailypolitical.com/2016/11/30/nivalis-therapeutics-inc-nvls-downgraded-by-cowen-and-company-to-market-perform.html.

In other Nivalis Therapeutics news, EVP David Malcom Rodman sold 5,820 shares of Nivalis Therapeutics stock in a transaction that occurred on Tuesday, October 4th. The shares were sold at an average price of $7.96, for a total transaction of $46,327.20. Following the completion of the sale, the executive vice president now directly owns 18,056 shares in the company, valued at approximately $143,725.76. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.00% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. AXA boosted its position in Nivalis Therapeutics by 35.4% in the second quarter. AXA now owns 533,692 shares of the company’s stock valued at $2,455,000 after buying an additional 139,652 shares in the last quarter. Opaleye Management Inc. boosted its position in Nivalis Therapeutics by 160.0% in the second quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock valued at $1,287,000 after buying an additional 160,000 shares in the last quarter. BVF Inc. IL boosted its position in Nivalis Therapeutics by 24.5% in the second quarter. BVF Inc. IL now owns 1,926,443 shares of the company’s stock valued at $8,862,000 after buying an additional 379,700 shares in the last quarter. Paloma Partners Management Co purchased a new position in Nivalis Therapeutics during the second quarter valued at about $105,000. Finally, Bank of New York Mellon Corp boosted its position in Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock valued at $134,000 after buying an additional 1,189 shares in the last quarter. Institutional investors and hedge funds own 79.26% of the company’s stock.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.